This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Smokeless Unit & Pricing to Boost Altria's (MO) Q2 Earnings
by Zacks Equity Research
Altria's (MO) Q2 performance is likely to gain from RRPs, high pricing and saving initiatives.
Zacks Market Edge Highlights: MJ, YOLO, THCX, TLRY and CRON
by Zacks Equity Research
Zacks Market Edge Highlights: MJ, YOLO, THCX, TLRY and CRON
Cronos Group (CRON) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $14.99 in the latest trading session, marking a +0.33% move from the prior day.
Should You Buy a Cannabis ETF?
by Tracey Ryniec
There are now 3 pot ETFs with several more to launch soon. Is this a good way for investors to get exposure to the cannabis industry?
Cronos to Acquire Apotex's Manufacturing Plant in Winnipeg
by Zacks Equity Research
Cronos (CRON) inks deal to acquire fermentation and manufacturing facility in Winnipeg, Canada, from Apotex Fermentation Inc.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $15.29, moving -1.55% from the previous trading session.
CannTrust Falls as Health Canada Issues Non-Compliance Report
by Zacks Equity Research
Health Canada issues a non-compliance report on CannTrust (CTST) regarding its greenhouse facility in Pelham, Ontario, which is used for growing cannabis. Shares take a hit.
The Zacks Analyst Blog Highlights: GW, Scotts Miracle-Gro, Cronos, CannTrust and Canopy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW, Scotts Miracle-Gro, Cronos, CannTrust and Canopy
5 Picks Ahead of Key Congressional Hearing on Marijuana Laws
by Nalak Das
Several economists and market researchers believe that the four bills may pave the way for marijuana ETFs, which are likely to attract billions of dollars in investment.
Is Cronos Group (CRON) Stock Outpacing Its Finance Peers This Year?
by Zacks Equity Research
Is (CRON) Outperforming Other Finance Stocks This Year?
Cronos Group (CRON) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $16.02, marking a +0.25% move from the previous day.
What to Make of Constellation Brands (STZ) Stock Heading into Q1 Earnings
by Mitchell Moore
Constellation Brands Inc (STZ), a leading producer and marketer of alcoholic beverage brands, is expected to release its Q1 fiscal 2020 earnings results before the bell this Friday, June 28. Our Zacks Consensus Estimate calls for quarterly EPS of $2.07.
Cronos Group (CRON) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $15.79, marking a -1.86% move from the previous day.
The Zacks Analyst Blog Highlights: Canopy Growth, GW, Scotts Miracle-Gro, Cronos and Aurora
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth, GW, Scotts Miracle-Gro, Cronos and Aurora
Breakthrough in U.S. Marijuana Industry: 5 Likely Gainers
by Nalak Das
The marijuana industry has strong potential especially after its legalization for recreational and medicinal use.
Canopy Growth Earnings After Bell 6/20: Key Word Growth
by Daniel Laboe
CGC analysts are estimating an EPS of -0.17 and revenues of $71 million. Shareholders are voting today on whether to acquire Acreage Holdings, which could propel CGC one way or the other.
Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $15.85, marking a +0.86% move from the previous day.
What to Expect from Marijuana Giant Canopy Growth's (CGC) Q4 Earnings
by Zachary Stutler
Canopy's stock is up 58% YTD, but all of this growth came in the first month of the year and the stock has struggled to maintain the levels it hit earlier this year.
A Company's First Profit Can Mean Big Profits for Investors
by Benjamin Rains
Obviously, losing less money than the prior quarter is a positive sign, as it shows growth. Then firms hit a point where they grow and grow and eventually become profitable. These are the stocks that will likely see more demand from new investors...
Do Hemp Stocks Stand to Gain From a Weed-Liberal Illinois?
by Nitish Marwah
The marijuana legislation in Illinois would allow any resident of the state above the age of 21 to possess the novelty item.
Can Smokeless Unit Help Altria Pare Low Cigarette Sales?
by Zacks Equity Research
Altria (MO) is undertaking efforts to expand in the RRPs space amid receding cigarette shipping volumes.
FDA to Hold First Public Hearing on Cannabis: 5 Likely Gainers
by Nalak Das
Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.
Marijuana ETFs Head-to-Head
by Neena Mishra
Here is what investors need to know about cannabis investing and the two ETFs that provide exposure to the space.
Buy Marijuana Stocks, Tilray & Aurora Cannabis, Before Earnings?
by Benjamin Rains
The legal marijuana industry is still in the early stages, so let's see if investors should consider buying some pure-play marijuana stocks heading into earnings.
Cronos Group (CRON) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 1900.00% and 3.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?